Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

被引：16
|
作者：
Sandoval-Sus, Jose D. [1 ]
Chavez, Julio C. [2 ]
Dalia, Samir [3 ]
Bello, Celeste M. [4 ]
Shah, Bijal D. [2 ]
Ho, Viet Q. [2 ]
Nodzon, Lisa [4 ]
Kharfan-Dabaja, Mohamed A. [5 ]
Sotomayor, Eduardo M. [6 ]
Sokol, Lubomir [7 ]
Pinilla-Ibarz, Javier [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA
[3] Mercy Clin Oncol & Hematol, Joplin, MO USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA
[6] George Washington Univ, Ctr Canc, Div Hematol Oncol, Washington, DC USA
[7] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2945.2945
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
    Rigolin, Gian Matteo
    Olimpieri, Pier Paolo
    Summa, Valentina
    Celant, Simone
    Scarfo, Lydia
    Ballardini, Maria Pia
    Urso, Antonio
    Gambara, Silvia
    Cavazzini, Francesco
    Ghia, Paolo
    Cuneo, Antonio
    Russo, Pierluigi
    HEMASPHERE, 2024, 8 (10):
  • [2] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [3] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Brown, J. R.
    Eichhorst, B.
    Hillmen, P.
    Jurczak, W.
    Kazmierczak, M.
    Lamanna, N.
    O'Brien, S. M.
    Tam, C. S.
    Qiu, L.
    Zhou, K.
    Simkovic, M.
    Mayer, J.
    Gillespie-Twardy, A.
    Ferrajoli, A.
    Ganly, P. S.
    Weinkove, R.
    Grosicki, S.
    Mital, A.
    Robak, T.
    Osterborg, A.
    Yimer, H. A.
    Salmi, T.
    Wang, M. -D. -Y.
    Fu, L.
    Li, J.
    Wu, K.
    Cohen, A.
    Shadman, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
  • [4] Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
    UK CLL Forum
    HAEMATOLOGICA, 2016, 101 (12) : 1563 - 1572
  • [5] Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
    Maddocks, Kami J.
    Ruppert, Amy S.
    Lozanski, Gerard
    Heerema, Nyla A.
    Zhao, Weiqiang
    Abruzzo, Lynne
    Lozanski, Arletta
    Davis, Melanie
    Gordon, Amber
    Smith, Lisa L.
    Mantel, Rose
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Jaglowski, Samantha M.
    Andritsos, Leslie A.
    Awan, Farrukh
    Blum, Kristie A.
    Grever, Michael R.
    Johnson, Amy J.
    Byrd, John C.
    Woyach, Jennifer A.
    JAMA ONCOLOGY, 2015, 1 (01) : 80 - 87
  • [6] Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
    O'Brien, Susan M.
    Furman, Richard R.
    Coutre, Steven E.
    Flinn, Ian W.
    Burger, Jan
    Blum, Kristie
    Sharman, Jeff
    Wierda, William G.
    Jones, Jeffrey
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Luan, Ying
    James, Danelle F.
    Chu, Alvina D.
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [7] Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 9 - 11
  • [8] IBRUTINIB IN THE MANAGEMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A REAL-LIFE MONOCENTRIC EXPERIENCE
    Albi, E.
    Del Papa, B.
    Dorillo, E.
    Aureli, P.
    Cantelmi, M. G.
    Zei, T.
    Ostini, R. Iacucci
    Ciurnelli, R.
    Falzetti, F.
    Sportoletti, P.
    HAEMATOLOGICA, 2017, 102 : 123 - 123
  • [9] IBRUTINIB EXPERIENCE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA: SINGEL CENTER EXPERIENCE
    Uysal, A.
    Soyer, N. Akad
    Patir, P.
    Duran, M.
    Koseoglu, F. D.
    Sahin, F.
    Vural, F.
    Tombuloglu, M.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S35 - S35
  • [10] Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
    Jain, Preetesh
    Keating, Michael
    Wierda, William
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    George, Binsah
    James, Danelle
    Kantarjian, Hagop
    Burger, Jan
    O'Brien, Susan
    BLOOD, 2015, 125 (13) : 2062 - 2067
12345